Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
17 evidence topics · 16 sources
Summary
- Durability: ICER's model analysis plan assumes that the treatment effect remains constant over the lifetime horizon and does not model discontinuation of a one-time gene therapy. Clinical experts noted that because neurons do not divide, the treatment effect may persist, while substantial uncertainty remains around long-term efficacy. ICER models TFC because there is no established mapping from the cUHDRS to costs, utilities, or mortality.
- Endpoints: a decline of 1.2 points on the cUHDRS is recommended as an estimate of meaningful within-patient decline in early manifest HD. The sponsor reports that the FDA continued to support the cUHDRS as an acceptable registrational, intermediate clinical endpoint for accelerated approval, and a votoplam trial uses change from baseline up to month 36 in the cUHDRS as its primary endpoint. ICER's outcomes of interest include procedure-related adverse events (headache, complications, pain) and post lumbar puncture syndrome.
- Interpretation of external comparisons: a placebo response in cognitive scores also influences the cUHDRS, and comparisons of trial data with retrospective natural history studies can mislead in distinguishing placebo response from drug effect. FDA draft guidance states that changes in the understanding of a disease's natural history can introduce bias in an externally controlled trial. Of forty-five FDA approvals that accepted external control data, retrospective natural history data were the most common source (44%) and 87% used an objective primary endpoint. Commentators cite a possible medical response bias from more frequent clinic visits, unmatched differences such as caudate and putamen size, and very small numbers of treated patients at longer follow-up, and state that assumptions about how long the benefit lasts will heavily shape modeled results.
- Modeled long-term outcomes: in one model, hypothetical disease-modifying treatments led to cost savings in the PFD population and increased costs in the SF1 and SF2 populations by prolonging time spent in progressive HD states.
Durability of a one-time gene therapy: ICER modeling assumption and clinical expert input
Link between cUHDRS and long-term outcomes: ICER rationale for modeling Total Functional Capacity
Procedure-related outcomes in the ICER assessment
Placebo and practice effects when trial data are compared with natural history
“Of interest, the cognitive scores (SDMT, SWR) exhibited an even stronger placebo response that was sustained after the dosing period of the trial ended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to note that these effects also significantly influence the cUHDRS score, given that it is derived from a linear relationship between TFC, TMS, SDMT score, and SWR score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, our analysis also emphasizes the potential for misleading interpretations when comparing trial data with retrospective natural history studies, particularly in distinguishing placebo response from drug effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interpretation of externally controlled comparisons: FDA draft guidance
External controls in FDA approvals, 2000 to 2019: sources and endpoints
“Forty-five approvals were identified where FDA accepted external control data in their benefit/risk assessment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Retrospective natural history data, including retrospective reviews of patient records, was the most common source of external control (44%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The vast majority (87%) of cases identified utilized an objective measure as a primary endpoint.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the few cases where the endpoint was subjective, the benefit was so large it was unlikely to be due to chance alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Independent commentary on the natural history comparator and durability of AMT-130
Natural history-based evidence and assumed duration of benefit: Prilenia comment to ICER
Composite clinical progression measure in early Huntington's disease
“Use of a composite motor, cognitive, and global functional clinical outcome measure in HD provides an improved measure of clinical progression more related to measures of progressive brain atrophy and provides an opportunity for enhanced clinical trial efficiency relative to currently used individual motor, cognitive, and functional outcome measures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinically meaningful change on the cUHDRS
Regulatory acceptance of cUHDRS as an intermediate clinical endpoint: sponsor-reported FDA feedback
Phase 3 disease-modifying trial endpoint: votoplam INVEST-HD
Time to functional decline as an endpoint
Cognitive endpoints and regulatory meaningfulness
Aims of disease-modifying treatment and modeled long-term outcomes
“Potential disease-modifying treatments (DMTs) such as gene therapy (GTx), antisense oligonucleotides (ASOs), and small molecule–based therapeutic approaches aim to provide long-term health benefits for people with HD by slowing down, arresting, or even reverting disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although hypothetical DMTs led to cost savings in the PFD population by delaying the cost burdens of functional decline, they increased costs in SF1 and SF2 populations by prolonging time spent in expensive progressive HD states.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expected outcomes of symptomatic chorea treatment
“By integrating pharmacologic therapy with multidisciplinary care and holistic, goal-oriented communication about the impact of chorea, clinicians can meaningfully improve safety, independence, and quality of life for individuals and families affected by HD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote